

PATIENT SAFETY INFORMATION CARD

AstraZeneca 

Patients receiving SOLIRIS® should carry this card at all times.
Show this card to any doctor involved in your health care.

on 14/06/2023.

This document has been approved by Singapore Health Sciences Authority (HSA)

Vaccination Date _____

Tel. number _____

Physician name _____

Hospital where treated _____

Patient name _____

 AstraZeneca

AstraZeneca Singapore Pte Ltd
10 Kallang Avenue #12-10, Aperia Tower 2, Singapore 339510
Tel: +65 6812 4700 Fax: +65 6385 3050
SG-6406 SOL 14/06/2023



Important Safety Information for Patients Taking SOLIRIS® (eculizumab)

SOLIRIS® can lower the ability of your immune system to fight infections, **especially meningococcal infection, which requires immediate medical attention.** If you experience any of the following symptoms, you should **immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care center.**

- | | |
|--|---|
| <ul style="list-style-type: none">• headache with nausea or vomiting• headache with a stiff neck or stiff back• fever• rash | <ul style="list-style-type: none">• confusion• muscle aches with flu-like symptoms• eyes sensitive to light |
|--|---|



Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Even if you stop using SOLIRIS®, keep this card with you for 3 months after your last SOLIRIS® dose. Your risk of meningococcal infection may continue for several weeks after your last dose of SOLIRIS®.



Information for the Treating Physician



This patient has been prescribed SOLIRIS® (eculizumab) therapy, which increases the patient's susceptibility to meningococcal infection (*Neisseria meningitidis*) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early.
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary.**
- Contact prescribing physician (refer to back of card) as soon as possible.

For more information about SOLIRIS®, please refer to the Package Insert (PI) or e-mail: MedInfo.SG@astrazeneca.com.

In case of safety concerns, please call +65 6812 4700 or e-mail: PatientSafety.SG@astrazeneca.com.